Editas Medicine (EDIT) FCF Margin (2015 - 2025)

Editas Medicine (EDIT) has 11 years of FCF Margin data on file, last reported at 408.9% in Q3 2025.

• On a quarterly basis, FCF Margin rose 8674684.0% year-over-year to 408.9% in Q3 2025; TTM through Sep 2025 was 379.7%, a 8529.0% decrease from a year earlier, with the FY2024 full-year figure at 640.34%, down 46687.0% from the prior year.
• FCF Margin for Q3 2025 stood at 408.9%, up from 1432.0% in the prior quarter.
• Over the last five years, FCF Margin for EDIT reached as high as 36.91% in Q4 2023 and fell as low as 114976.19% in Q3 2022.
• Historically, FCF Margin has averaged 12498.51% across 5 years, with a median of 760.23% in 2022.
• Across the five-year window, FCF Margin plunged 11432952 bps in 2022 and surged 11430719 bps in 2023, its largest moves.
• Year by year, FCF Margin stood at 277.59% in 2021, then slumped by 122 bps to 616.62% in 2022, then surged by 94 bps to 36.91% in 2023, then tumbled by 318 bps to 154.43% in 2024, then plunged by 165 bps to 408.9% in 2025.
• Per Business Quant data, the three most recent FCF Margin figures were 408.9% in Q3 2025, 1432.0% in Q2 2025, and 1004.16% in Q1 2025.